51
|
|
52
|
Jin K, Li H, Volpe J, Emlet D, Pastor-Soler N, Pinsky MR, Zuckerbraun BS, Hallows K, Kellum JA, Gomez H. Is acute kidney injury in the early phase of sepsis a sign of metabolic downregulation in tubular epithelial cells? Crit Care 2015. [PMCID: PMC4471089 DOI: 10.1186/cc14366] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
53
|
Yajnik V, Gomez H. Prehospital induction of mild hypothermia with cold normal saline for cardiac arrest: more harm than good? CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2014; 18:559. [PMID: 25673524 PMCID: PMC4330983 DOI: 10.1186/s13054-014-0559-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
54
|
Escobar DA, Botero-Quintero AM, Kautza BC, Luciano J, Loughran P, Darwiche S, Rosengart MR, Zuckerbraun BS, Gomez H. Adenosine monophosphate-activated protein kinase activation protects against sepsis-induced organ injury and inflammation. J Surg Res 2014; 194:262-72. [PMID: 25456115 DOI: 10.1016/j.jss.2014.10.009] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Revised: 09/18/2014] [Accepted: 10/03/2014] [Indexed: 01/20/2023]
Abstract
BACKGROUND Mortality in sepsis is most often attributed to the development of multiple organ failure. In sepsis, inflammation-mediated endothelial activation, defined as a proinflammatory and procoagulant state of the endothelial cells, has been associated with severity of disease. Thus, the objective of this study was to test the hypothesis that adenosine monophosphate-activated protein kinase (AMPK) activation limits inflammation and endothelium activation to protect against organ injury in sepsis. 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), which is an adenosine monophosphate analog, has been used to upregulate activity of AMPK. Compound C is a cell-permeable pyrrazolopyrimidine compound that inhibits AMPK activity. METHODS Wild-type mice underwent cecal ligation and puncture (CLP) or sham surgery. Mice were randomized to vehicle, AICAR, or compound C. Mouse kidney endothelial cells were used for in vitro experiments. Renal and liver function were determined by serum cystatin C, blood urea nitrogen (BUN), creatinine, and alanine aminotransferase. Serum cytokines were measured by enzyme-linked immunosorbent assay. Microvascular injury was determined using Evans blue dye and electron microscopy. Immunohistochemistry was used to measure protein levels of phospho-AMPK (p-AMPK), microtubule-associated protein 1A/1B-light chain 3 (LC3), and intracellular adhesion molecule. LC3 levels were used as a measure of autophagosome formation. RESULTS AICAR decreased liver and kidney injury induced by CLP and minimized cytokine elevation in vivo and in vitro. CLP increased renal and hepatic phosphorylation of AMPK and autophagic signaling as determined by LC3. Inhibition of AMPK with compound C prevented CLP-induced autophagy and exacerbated tissue injury. Additionally, CLP led to endothelial injury as determined by electron microscopy and Evans blue dye extravasation, and AICAR limited this injury. Furthermore, AICAR limited CLP and lipopolysaccharide (LPS)-induced upregulation of intracellular adhesion molecule in vivo and in vitro and decreased LPS-induced neutrophil adhesion in vitro. CONCLUSIONS In this model, activation of AMPK was protective, and AICAR minimized organ injury by decreasing inflammatory cytokines and endothelial activation. These data suggest that AMPK signaling influences sepsis or LPS-induced endothelial activation and organ injury.
Collapse
|
55
|
Gomez H, Escobar D, Botero A, Zuckerbraun BS. AMP-protein kinase may protect against sepsis-induced acute kidney injury through modulation of immune response and endothelial activation. Crit Care 2014. [PMCID: PMC4068381 DOI: 10.1186/cc13425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
56
|
Haugaa H, Gomez H, Maberry D, Holder A, Ogundele O, Botero A, Escobar D, Gordon L, Shiva S, Dezfulian C, Kenney B, Tønnessen TI, Zuckerbraun B, Pinsky MR. Attenuation of ischemia-reperfusion injury in swine resuscitated for hemorrhagic shock by low-dose inhaled nitrite or carbon monoxide. Crit Care 2014. [PMCID: PMC4068305 DOI: 10.1186/cc13309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
57
|
Gomez H, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, Santi PX, Pinczowsky H, Neron Y, Fanelli M, Fein L, Sampaio C, Lerzo G, Capo A, Zarba JJ, Blajman C, Varela MS, Martínez-Mesa J, Werutsky G, Barrios CH. Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-12-26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Lapatinib-Capecitabine (LC) is approved for the treatment of advanced or metastatic breast cancer (MBC) whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane (T), and trastuzumab (H). LACOG 0801 evaluated different L-based chemotherapies as first and second-line treatments in MBC.
Methods:
This is a randomized, open label, multicenter, phase II trial of L 1250 mg BID given continuously in combination with C 2000 mg/m2 d1-14 (LC), or Vinorelbine (V) 25mg/m2 d1 and 8 (LV) or Gemcitabine (G) 1000 mg/m2 d1 and 8 (LG), in 21 days cycles. Primary endpoint was ORR (RECIST). Secondary endpoints included progression free survival (PFS), overall survival, tolerability and safety. Patients with HER2 positive MBC who had failed a T-based treatment and who had ≤1 chemotherapy regimen in the metastatic setting were included. Prior therapy with H was not mandatory. Patients were stratified by the presence of liver metastasis, previous use of H, and T administered in the neo/adjuvant or the metastatic setting. With an expected ORR of 23% in the control arm (LC), we hypothesized an absolute increase of 12% in the experimental arms using Simon's design.
Results:
A total of 142 pts from Argentina, Brazil and Peru were included from 2009-2012. Patient baseline characteristics were well balanced between the three arms. Median age was 51y, 58% postmenopausal, 65% ECOG 1, 49% had visceral disease (32% liver metastasis), 57% hormone receptor negative and only 47% had received prior H. Median number of administered cycles was 6 (LC = 5; LV = 7; LG = 6). ORR was 47.1% (95%CI 38.5; 67.1), 55.6% (95%CI 29.6; 60.0) and 41.3% (95%CI 43.2; 73.0) in LC, LV and LG, respectively. Median PFS was 9.1m (95%CI 6.1; 14.7), 7.0m (95%CI 5.0; 9.9) and 6.8m (95%CI 5.8; 9.9) in LC, LV and LG arms respectively. Survival data will be updated. The proportion of patients with at least one adverse event (AE) was 96% in all arms. Most common all grade AE were diarrhea (76%), hand-foot syndrome (HFS) (45%) and vomiting (39%) in LC; diarrhea (71%), neutropenia (68%) and nausea (43%) in LV; diarrhea (64%), neutropenia (60%), anemia and increased ALT both 44% in LG. The most frequent grade 3 and 4 AEs were HFS (18%), diarrhea (6%) and increased ALT/AST (4%) in LC; neutropenia (36%), diarrhea (9%) and febrile neutropenia (6%) in LV; and neutropenia (47%), ALT/AST elevation (13%) and rash (4%) in LG. Discontinuation due to toxicity occurred in 16%, 7% and 20% of patients in arms LC, LV and LG respectively.
Conclusion:
LV and LG seems to be active combinations in patients with HER2 positive MBC after T failure. The high ORR observed in this study might be explained, among other factors, by the inclusion of patients with less prior treatment exposure. No new safety signals where reported with these two novel Lapatinib/chemotherapy combinations. The different side effect profile may help in selecting the most appropriate regimen for a particular patient.
Sponsor: Latin American Cooperative Oncology Group (LACOG) with support from GlaxoSmithKline.
ClinicalTrials.gov number NCT01050322.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-26.
Collapse
|
58
|
Awada A, Spector N, El-Hariry I, Rodriguez AA, Erban JK, Cortes J, Gomez H, Kong A, Hickish T, Fein L, Vahdat L, MacPherson I, Canon JL, Mansoor S, Giovanne A, McAdam K, Vukovic VM, Yalcin I, Bradley R, Proia D, Mano MS, Perez EA, Cameron DA. Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-16-23] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Hsp90 is a molecular chaperone protein required for the stabilization and activation of many proteins, referred to as Hsp90 ‘clients’, such as HER2, HIF1-a, EGFR, ER, PI3K, AKT, P53 and VEGFR. The drug candidate, ganetespib is a novel triazolone inhibitor of Hsp90, with over 700 patients treated to date. Ganetespib has shown activity in preclinical models of HER2+, ER+/PR+ and TNBC. Early clinical trials documented ganetespib single agent activity in heavily pretreated HER2+ and TNBC patients. Ganetespib has been well tolerated in clinical trials with a favorable safety profile. This efficacy-screening study is designed to provide further evidence of ganetespib activity and identify potentially predictive biomarkers in metastatic breast cancer (BC).
Methods: The ENCHANT-1 Trial is an international, first-line 2-cohort Phase 2 study in BC patients: Cohort A, HER2 amplified (n = 35), and Cohort B, TNBC (n = 35). Patients who present with previously untreated metastatic disease are eligible for treatment with ganetespib at 150 mg/m2 twice weekly on 3 out of 4 wks, for a total of up to 12 wks. Primary endpoint: ORR assessed using RECIST1.1 criteria. Key secondary endpoints include metabolic response as assessed by PET/CT at wk 3 utilizing modified EORTC criteria. Disease progression (PD) at wk 3 by PET imaging indicates discontinuation of study therapy, and is performed to quickly offer patients with metabolic PD a standard of care treatment.
The study is designed as Simon 2-stage requiring at least one OR in 15 patients for the respective cohort to expand to 35 patients. A Steering Committee is established to oversee the overall study and review the interim results.
Results: The study was initiated in 23 centers globally. At the time of submission, a total of 17 patients had been enrolled; TNBC (n = 15) and HER2 (n = 2). Here we report the interim analysis in the TNBC cohort. The median age was 54 years (range 30 -77) with ECOG PS 0 (n = 7/15). Most patients (n = 9) presented with de novo metastatic disease. 5 patients were not evaluable for PET assessment (3 had not yet reached wk 3 and 2 withdrawn before wk 3 for clinical progression), and 9 patients were not evaluable for objective response at wk 6 (3 withdrawn before or at wk 3 for clinical progression and 6 had not yet reached wk 6 evaluation). In the 10 patients with evaluable PET imaging, 9 patients achieved metabolic (m) response (2 mPR, 4 mSD with dominant tumor shrinkage and 3 SD) and one patient with mPD. In the 6 patients evaluable for OR at wk 6, one patient achieved PR, 2 SD and 3 PD. Treatment with ganetespib was well tolerated; the most common AEs were mild or moderate diarrhea (8/15, 53%), fatigue (5/15, 33%), decreased appetite (4/15, 27%), insomnia (4/15, 27%), and nausea (4/15, 27%).
Conclusion: Ganetespib single agent was generally well tolerated and showed anti-tumor activity TNBC patients as early as 3 weeks following treatment. PET seems to be a good tool to screen antitumor activity of new agents in early settings rather that in heavily pretreated patients. The TNBC cohort has met the protocol criteria for proceeding to stage 2.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-23.
Collapse
|
59
|
Whelan SP, Carchman EH, Kautza B, Nassour I, Mollen K, Escobar D, Gomez H, Rosengart MA, Shiva S, Zuckerbraun BS. Polymicrobial sepsis is associated with decreased hepatic oxidative phosphorylation and an altered metabolic profile. J Surg Res 2013; 186:297-303. [PMID: 24054495 DOI: 10.1016/j.jss.2013.08.007] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2013] [Revised: 08/01/2013] [Accepted: 08/08/2013] [Indexed: 11/16/2022]
Abstract
BACKGROUND Organ failure in sepsis accounts for significant mortality worldwide. Mitochondrial and metabolic responses are central to the overall response of the cell, and thus of the organ and organism. Adaptive responses in metabolism are critical to the recovery at the cellular level. The purpose of these investigations was to test the hypothesis that sepsis is associated with decreased aerobic respiration and significant metabolic changes in the liver. METHODS C57BL/6 mice underwent cecal ligation and puncture (CLP) with a 21 gauge needle or an operation without CLP. Mice were euthanized from 0-24 h after the procedure and liver tissue was harvested. Tissue oxygen consumption and mitochondrial complex activity were measured. Global biochemical profiles of 311 metabolites were performed at the 8-h time point (n = 8/group) and analyzed by gas chromatography-mass spectrometry and liquid chromatography tandem mass spectrometry platforms by Metabolon (Durham, North Carolina). The influence of lipopolysaccharide (LPS) on aerobic and anaerobic respiration in primary mouse hepatocytes was also investigated. RESULTS CLP in vivo or LPS in vitro resulted in a significant decrease in hepatic oxygen consumption. There was a significant decrease in oxidative phosphorylation measured at 12 h. LPS also resulted in a significant increase in anaerobic respiration in hepatocytes. Interestingly, the metabolomic analysis resulted in a metabolic shift in the liver from carbohydrate-based energy to utilization of fatty acids and amino acids. This included an increase in every tricarboxylic acid cycle intermediate and derivative, suggesting an increased flux into the cycle from fatty acid beta-oxidation and anaplerotic contributions from amino acids. CONCLUSIONS Sepsis results in a metabolic response and profile consistent with increased anaerobic respiration, which occurs prior to significant changes in hemodynamics. The metabolic responses of cells and organs may be important adaptive responses to prevent organ failure and death.
Collapse
|
60
|
Howell GM, Gomez H, Collage RD, Loughran P, Zhang X, Escobar DA, Billiar TR, Zuckerbraun BS, Rosengart MR. Augmenting autophagy to treat acute kidney injury during endotoxemia in mice. PLoS One 2013; 8:e69520. [PMID: 23936035 PMCID: PMC3728340 DOI: 10.1371/journal.pone.0069520] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2013] [Accepted: 06/11/2013] [Indexed: 01/08/2023] Open
Abstract
Objective To determine that 1) an age-dependent loss of inducible autophagy underlies the failure to recover from AKI in older, adult animals during endotoxemia, and 2) pharmacologic induction of autophagy, even after established endotoxemia, is of therapeutic utility in facilitating renal recovery in aged mice. Design Murine model of endotoxemia and cecal ligation and puncture (CLP) induced acute kidney injury (AKI). Setting Academic research laboratory. Subjects C57Bl/6 mice of 8 (young) and 45 (adult) weeks of age. Intervention Lipopolysaccharide (1.5 mg/kg), Temsirolimus (5 mg/kg), AICAR (100 mg/kg). Measurements and Main Results: Herein we report that diminished autophagy underlies the failure to recover renal function in older adult mice utilizing a murine model of LPS-induced AKI. The administration of the mTOR inhibitor temsirolimus, even after established endotoxemia, induced autophagy and protected against the development of AKI. Conclusions These novel results demonstrate a role for autophagy in the context of LPS-induced AKI and support further investigation into like interventions that have potential to alter the natural history of disease.
Collapse
|
61
|
Galenko PK, Gomez H, Kropotin NV, Elder KR. Unconditionally stable method and numerical solution of the hyperbolic phase-field crystal equation. PHYSICAL REVIEW. E, STATISTICAL, NONLINEAR, AND SOFT MATTER PHYSICS 2013; 88:013310. [PMID: 23944586 DOI: 10.1103/physreve.88.013310] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2013] [Indexed: 05/11/2023]
Abstract
The phase-field crystal model (PFC model) resolves systems on atomic length scales and diffusive time scales and lies in between standard phase-field modeling and atomistic methods. More recently a hyperbolic or modified PFC model was introduced to describe fast (propagative) and slow (diffusive) dynamics. We present a finite-element method for solving the hyperbolic PFC equation, introducing an unconditionally stable time integration algorithm. A spatial discretization is used with the traditional C^{0}-continuous Lagrange elements with quadratic shape functions. The space-time discretization of the PFC equation is second-order accurate in time and is shown analytically to be unconditionally stable. Numerical simulations are used to show a monotonic decrease of the free energy during the transition from the homogeneous state to stripes. Benchmarks on modeling patterns in two-dimensional space are carried out. The benchmarks show the applicability of the proposed algorithm for determining equilibrium states. Quantitatively, the proposed algorithm is verified for the problem of lattice parameter and velocity selection when a crystal invades a homogeneous unstable liquid.
Collapse
|
62
|
Phillips DP, Kaynar AM, Kellum JA, Gomez H. Crystalloids vs. colloids: KO at the twelfth round? CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2013; 17:319. [PMID: 23731998 PMCID: PMC3706790 DOI: 10.1186/cc12708] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Expanded abstract
Collapse
|
63
|
Mian M, Gaidano G, Rossi A, Cabrera ME, Federico M, Martelli M, Gomez H, Lopez-Guillermo A, Tsang R, Zucca E, Cavalli F, Cortelazzo S. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Pneumologie 2013. [DOI: 10.1055/s-0033-1345067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
64
|
Gomez H, Escobar D, Ataya B, Gordon L, Ogundele O, Pinsky M, Shiva S, Zuckerbraun B. Inhaled carbon monoxide or nebulized sodium nitrite protect against hemorrhagic shock-induced mitochondrial dysfunction. Crit Care 2013. [PMCID: PMC3642532 DOI: 10.1186/cc12158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
65
|
Kaynar A, Phillips D, Gomez H, Lischner M, Melhem S, Subramaniam K, Pinsky M. Utility of transesophageal echocardiography in the ICU: a preliminary US perspective. Crit Care 2013. [PMCID: PMC3642394 DOI: 10.1186/cc12120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
66
|
Gomez A, Leon A, Fernandez G, Montenegro G, Gomez H. Pressure support ventilation with minimal sedation as the main ventilatory mode in critically ill patients with lung injury: effect on mortality and incidence of complications. Crit Care 2013. [PMCID: PMC3643180 DOI: 10.1186/cc12034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
67
|
Balko JM, Wang K, Sanders ME, Kuba MG, Pinto JA, Doimi F, Gomez H, Palmer G, Cronin MT, Miller VA, Yelensky R, Stephens PJ, Areaga CL. Abstract S3-6: Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-s3-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NAC) is increasingly used in patients with triple-negative breast cancer (TNBC). NAC can induce a pathologic complete response (pCR) in ∼30% of patients which portends a favorable prognosis. In contrast, patients with residual disease (RD) in the breast at surgical resection exhibit worse outcomes.
Objective: We hypothesized that profiling residual TNBCs after NAC would identify molecularly targetable lesions in the chemotherapy-resistant component of the tumor and that the persistent tumor cells would mirror micro-metastases which ultimately recur in such patients.
Methods: We utilized targeted next generation sequencing (NGS) for 182 oncogenes and tumor suppressors in a CLIA certified lab (Foundation Medicine, Cambridge, MA) and gene expression profiling (NanoString) of the RD after NAC in 102 patients with TNBC. The RD was stained for Ki67, which has been reported to predict outcome after NAC in unselected breast cancers.
Results: Thirteen tumors were not evaluable due to low tumor cellularity. Of 89 evaluable post-NAC tumors, 57 (64%) were basal-like; 19% HER2-enriched; 6% luminal A; 6% luminal B and 5% normal-like. Mean depth of coverage was 635 (range: 135–1207). Of 81 tumors evaluated by NGS, 72/81 (89%) demonstrated mutations in TP53, 22 were MCL1-amplified (27%), and 17 were MYC-amplified (21%). Alterations in the PI3K/mTOR pathway (AKT1-3, PIK3CA, PIK3R1, RAPTOR, PTEN, and TSC1) were identified in 27 tumors (33%). Cell cycle genes were altered in 25 tumors (31%), including amplifications of CDK2, CDK4, and CDK6, CCND1-3, and CCNE1 as well as RB loss. Alterations in the DNA repair pathway (BRCA1/2, ATM; 16 tumors; 20%) and the Ras/MAPK pathway (KRAS, RAF1, NF1; 10 tumors; 12%) were also common. Sporadic growth factor receptor amplifications occurred in EGFR, KIT, PDGFRA, PDGFRB, MET, FGFR1, FGFR2, and IGF1R. NGS identified 7 patients with ERBB2 gene amplification in the RD which was confirmed by FISH in both the pre- and post-treatment tissue, suggesting NGS could assist in the identification of ERBB2-overexpressing tumors misclassified at the time of diagnosis. In general, the gene amplifications identified by NGS corresponded to enhanced gene expression levels. Amplifications of MYC were independently associated with poor recurrence-free survival (RFS) and overall survival (OS). An interaction effect on survival was observed between MEK activation (assayed by a gene expression signature) and MYC amplification, suggesting cooperation between these pathways. Alterations in DNA repair also identified a subgroup with poor RFS and OS. In contrast, high post-NAC Ki67 score did not predict poor RFS or OS in this predominantly TNBC cohort.
Conclusions: The diversity of lesions in residual TNBCs after NAC underscores the need for powerful and broad molecular approaches to identify actionable molecular alterations and, in turn, better inform personalized therapy of this aggressive disease. Incorporation of this platform into clinical studies and eventually standards of care should aid in the prioritization of patients with RD after NAC into rational adjuvant studies.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr S3-6.
Collapse
|
68
|
Rugiero M, Bettini M, Salutto VL, Gomez H, Pirra L, Politei J, Dubrovsky A, Reisin R, Nogues M, Mazia C. Clinical and Demographical Findings of MuSK Myasthenia Gravis in Argentina (P05.175). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p05.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
69
|
Baselga J, Costa F, Gomez H, Hudis C, Rapoport B, Roche H, Schwartzberg L, Petrenciuc O, Shan M. 257 Design of RESILIENCE: a Phase 3 TRial Comparing CapecitabinE in Combination with SorafenIb or PLacebo for Treatment of Locally Advanced or MetastatIc HER2-Negative Breast CancEr. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70324-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
70
|
Gomez H, Nassour I, Loughran P, Brumfield J, Otterbein L, Zuckerbraun B. Carbon monoxide therapy protects against hepatic microvascular injury in a mouse model of murine hemorrhagic shock and resuscitation. Crit Care 2012. [PMCID: PMC3363682 DOI: 10.1186/cc10871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
71
|
Balko JM, Cook RS, Kuba MG, Miller TW, Bhola NE, Sanders ME, Meszoely IM, Dowsett M, Gomez H, Arteaga CL. PD08-03: Inhibition of MEK/ERK- and JNK-Dependent Expression of Interleukin-6 and Interleukin-8 Targets Basal-Like Breast Cancer Stem Cells. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-pd08-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NAC) induces a pathological complete response in approximately 30% of triple-negative or basal-like breast cancers (BLBC). However, patients with residual disease often recur after surgery, presumably due to persistent drug-resistant subpopulations with cancer stem cell (CSC)-like properties. Thus, elimination of this CSC compartment in BLBC has the potential to improve survival by reducing post-surgical metastatic recurrences.
Methods: We sampled 49 post-NAC breast cancer samples including 22 BLBCs and quantified RNA for 355 cancer-related transcripts using Nanostring technology. Transcripts associated with a high Ki67 in the residual disease (a biomarker of early recurrence) were identified and bioinformatically examined for an association with drug resistance and a CSC phenotype. Loss of DUSP4, a negative feedback regulator of ERK1/2 and JNK1/2, was highly associated with a high post-NAC Ki67. We examined the role of loss of DUSP4 in promoting a drug-resistant, CSC phenotype.
Results: Low DUSP4 expression in post-NAC tumors was associated with high ERK1/2 activation and BLBC gene expression. siRNA knockdown of DUSP4 enhanced resistance to anti-cancer chemotherapy (docetaxel, camptothecin). Alternatively, forced DUSP4 expression in breast cancer cell lines abrogated the activation of transcription factors downstream of ERK and JNK and sensitized cells to docetaxel-induced apoptosis. In highly metastastic BLBC cell lines, MEK inhibition with AZD6244 and JNK inhibition with SP600125 significantly reduced mammosphere formation and self-renewal. Inhibition of JNK and MEK reduced IL6 and IL8 expression, two cytokines known to expand the CSC compartment. Reconstitution of exogenous IL6 and IL8 after MEK inhibition restored mammosphere formation potential. Chromatin immunoprecipitation demonstrated that the oncogenic transcription factor ETS-1, an ERK1/2 substrate, binds the IL8 promoter in a MEK1/2-dependent manner. We are currently confirming the association of DUSP4 loss with Ki67, ERK activation, and IL6/IL8 expression in a cohort of 113 post-NAC triple negative breast cancers. Conclusions: Our data demonstrate that loss of DUSP4 in BLBC promotes ERK and JNK activation by impairing negative feedback of these pathways. Activation of ERK and JNK drives expression of IL6 and IL8 expression, possibly through ETS-1 activation. Thus, targeting these signaling pathways may eliminate residual cancer stem cells after neoadjuvant chemotherapy and improve cure rates in BLBC.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD08-03.
Collapse
|
72
|
Vahdat LT, Vrdoljak E, Gomez H, Li RK, Thomas E, Bosserman LD, Sparano JA, Baselga J, Mukhopadhyay P, Valero V. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
73
|
Neciosup SP, Ventura L, Gomez H, Pinto JA, Marcelo MJ, Vidaurre T, Vallejos Sologuren C. Responses rates and outcome to neoadjuvant chemotherapy in triple-negative breast cancers (TNBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
74
|
Vidaurre T, Calderón M, Mantilla R, Vigil CE, León M, Más L, Montanez M, Neciosup SP, Gomez H. Prognostic value of the ratio of positive axillary lymph node after neoadjuvant chemotherapy in Peruvian patients with breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
75
|
Schwarz LJ, Vidaurre T, Neciosup SP, Pinto JA, Ferreyros G, Gomez H. Risk factors for outcome in Hispanic patients with breast cancer with central nervous system (CNS) metastases. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|